o-The influence of diltiazem on chronic cerebral vasospasm was studied following subarachnoid hemorrhage (SAH) in a primate model. The model mimics the human experience including the production of neurological deficits. Six monkeys were pretreated with diltiazem (25 mg/kg twice daily) for 2 days prior to surgical production of an SAH and for 5 days after the hemorrhage. This group was compared with six untreated monkeys that also sustained an SAH. The mean diameter of cerebral arteries measured at six angiographic sites was 60.6% of the pre-SAH diameter for the untreated group and 99.7% for the diltiazem-treated group. These values are significantly different (p < 0.0005). There was no neurological deficit in the pretreated animals. The mean diameter of the "most constricted vessel" in each experiment was 22% of the prehemorrhage diameter for the untreated and 84% for the treated group (p < 0.0005). Arterial pressure was unaffected by the dosage regimen. These experiments with this primate model of chronic cerebral vasospasm demonstrate that vascular narrowing and neurological deficit can be markedly attenuated by diltiazem pretreatment.
C
EREBRAL vasospasm continues to complicate the neurosurgical treatment of subarachnoid hemorrhage (SAH). It increases the risks of early surgery, and may force a delay of operation for days or weeks, exposing the patient to the danger of recurrent SAH and death. 9,~ 1,13,16,21,22 Considerable effort has been expended to understand this condition and to design an effective mode of treatment for it. Many therapies have been tried, 22 but thus far none has been consistently successful. 2'5'8 One approach to understanding cerebral vasospasm has been experimentation with animal models, but to date no model has successfully re-created the human syndrome. Most authors 8'~4'2~ agree that such a model should include the use of a primate, the reliable production of vasoconstriction without causing death, the use of a technique that injures the vessel wall and produces hemorrhage, the angiographic demonstration of vasospasm occurring after a delay of a few days with constriction of one or more vessels to at least 50% of their control size, and the persistence of vasospasm for many days to a few weeks. In addition, the model should include an appropriate neurological deficit, but this last condition has consistently been absent in animal models. Our laboratory has developed a model that fulfills all of these criteria. We have recently used the model to study the efficiency of diltiazem, a synthetic calcium channel blocker, in preventing cerebral vasospasm.
Diltiazem has been found to selectively relax cerebral vascular smooth muscle, while not affecting other regional vascular beds? This effect presumably reflects the specific action of this compound on the calcium entry mechanisms: probably the receptor-operated and potential-sensitive channels in cerebral vascular muscle. This finding prompted us to determine whether diltiazem pretreatment would influence the extent of vasoconstriction that occurs in our experimental model, The decision to study the effect of diltiazem pretreatment first, rather than the effect of its administration after SAH, was predicated on a desire to understand the etiology of the pathological state. There is considerable evidence that chronic cerebral vasospasm may be related to the effect of various vasoactive materials on the cells of cerebral blood vessels 22 --an action against which diltiazem might be expected to play a therapeutic role. We have demonstrated the significant inhibition of an experimental form of chronic F1G. 1. Artist's concept of the fight internal carotid artery and optic nerve with a needle passing through both walls of the artery. An attached suture is used to remove the needle percutaneously, cerebral vasospasm in a primate model pretreated with diltiazem.
Materials and Methods

Model Preparation
Twelve adult Macaca nemestrina monkeys were separated randomly into two equal groups without regard for age or sex. Six monkeys were treated with diltiazem. On the 1 st day, all the monkeys were lightly premedicated intramuscularly with ketamine (5 to 10 mg/kg) and atropine (0.1 rag). This treatment left them awake and responsive to stimuli, yet sufficiently cooperative to be examined. Prior to any manipulation, a baseline neurological examination was completed by two of us (J.G.F. and K.R.J.) and included cranial nerves, muscle tone, and reflexes. Mental status and activity were assessed by observation of the monkeys in their cages prior to administration of ketamine. An intravenous line was placed and the monkeys were anesthetized with a single dose of intravenous pentobarbital (5 to 8 mg/kg). Respirations were controlled with a Bird respirator* via an endotracheal tube, and heart rate, respirations, and body temperature were continuously monitored. Monkeys were warmed with a heating pad and temperatures were maintained at 38 ~ _+ 0.5~ Arterial blood gases were monitored and pCO2 was maintained at 40 _+ 5 mm Hg. Before diltiazem treatment and 2 and 8 days after treatment, arterial *Bird respirator manufactured by Bird Corp., Palm Springs, California. blood pressure was recorded from a femoral catheter, using a Statham transducer and a Sanborn two-channel recorder, t Under fluoroscopic control, a specially designed No. 5 French radiopaque polyethylene catheter was introduced via the femoral artery into the common carotid artery for carotid angiography. X-ray films were taken at two films/sec for 3 seconds while 5 ml of iothalamate meglumine (Conray 60) was hand-injected over 2 seconds. A metal measure was used with each film to insure constant magnification.
The following day, each of the monkeys in the treatment group was given diltiazem (25 mg/kg orally) twice each day. Compliance with this regimen was excellent when the diltiazem was mixed in apple juice to disguise its bitter taste. After 2 days of treatment, the neurological examination and blood pressure measurements were repeated under the conditions previously described. These tests were also performed on the untreated group. All 12 animals then underwent frontotemporal craniectomy under pentobarbital anesthesia. Hyperventilation and mannitol (1 gm/kg intravenously) facilitated brain retraction. After the arachnoid had been opened, a 0.4-mm round stainless steel needle was placed under magnification through both walls of the carotid artery (Fig. 1 ). An attached suture was buried subcutaneously, and the dura, muscle, and scalp were closed.
The following day, with all monkeys appearing well, they were again prepared with ketamine and examined neurologically. The needle was then withdrawn percutaneously to create an SAH. The monkeys were observed for 30 minutes before being returned to their cages. The diltiazem treatment was continued for 4 more days. On the 5th day, the monkeys were again prepared with ketamine and examined. They were then paralyzed and angiography was repeated. These anglograms were compared with the baseline controls. The monkeys were then sacrificed, and the brain and blood vessels were removed for further study.
Data Analysis
Measurements of arterial diameter were made from the angiograms at preselected sites (Fig. 2) using an optical micrometer, which magnified the vessels six times and was accurate to 0.1 m m . , All measurements were made by the same person (J.G.F.) without knowledge of the circumstances of the angiography, using a technique described by du Boulay.12 Vessels were measured at each site on three separate occasions and the results were averaged to provide a single value for that site. These mean values were expressed as a percent of the baseline arterial diameters in the same animal. The most constricted vessel in each animal was identified, and measurements of these vessels were combined to provide single values for the control and experimental phases. Comparisons of control and experimental results within groups were made using a paired Student t-test, and comparisons between the treated and untreated groups were made using the non-paired Student t-test. Significance was defined as p < 0.05.
Results
Neurological Examinations
All monkeys in both groups were neurologically normal at the time of the baseline examination and on the day following surgery, but prior to creating the SAH. Five days after the SAH, all untreated monkeys were hyperreflexic and hypotonic on the side contralateral to the SAH. None of the treated animals showed any neurological abnormality on Day 5.
Angiographic Results
The results of the measurements of the angiographic arterial diameters in the six untreated animals are presented in Table 1 , and Fig. 3 shows representative baseline and experimental angiograms from an untreated monkey. The averaged arterial diameters at each site for all experiments ranged from 33% to 80% of controls. The averaged diameters at each site were all significantly different from their control values. When all vessel diameters were combined, there was an average decrease in diameter of 39.4% (p < 0.0005).
The averaged diameters of the diltiazem-treated group are presented in Table 2 , and representative control and experimental angiograms are shown in Fig.  4 . They are mildly decreased in four animals and increased in two. Only one value is significantly less than its control. When all the vessels are grouped together, the diameter following the SAH is 99.7% of the baseline value. Table 3 shows a comparison of the averaged diameters for each location measured in the untreated and treated groups. The values at each measured site are significantly different.
The vessel that was most affected by the SAH in each monkey in the untreated group had an average diameter of 22% of its control ( Table 1 ). The equivalent vessel in the treated group was 84% of its control ( Table 2) . The difference between these two groups is statistically significant at the p < 0.0005 level.
Arterial Blood Pressure
Systolic and diastolic blood pressures before, during, and at the end of diltiazem treatment are presented in Table 4 . There was a mild drop in both pressures on Day 2, but they returned to the baseline level 8 days after diltiazem treatment was begun. These changes were not statistically significant.
Discussion
This paper presents a study using a primate model of chronic cerebral vasospasm following SAH. Unlike other models, the spasm obtained here is consistently accompanied by an appropriate delayed neurological deficit, seen as hypotonicity and hyperreflexia on the side contralateral to the SAH. Examination 24 hours after preparatory surgery confirmed that there was no deficit prior to the SAH. Previously described models may have been unsuccessful in producing severe cerebral vasospasm or a neurological deficit because 1) nonprimate animals with good collateral blood supply were used; 17 2) vessel injury did not accompany the SAH, 6 or 3) the SAH was not severe. 2~ The findings in the experimental animals not treated with diltiazem confirmed that chronic angiographic spasm was present at each site measured and could be quite severe. In sharp contrast, only the diameter of the distal middle cerebral artery of the diltiazem-treated group (reduced 7% after the SAH) was statistically different from its control. When the mean values for the untreated and treated groups were compared, there was significantly less spasm in the treated group at each arterial site measured. Thus, pretreatment with diltiazem in doses that have minimal effect on the blood pressure produces significant quantitative effects on cerebral vasoconstriction.
The most constricted vessel was identified in each animal, and the diameters of these vessels were combined to give an additional measure of the magnitude of the vasospasm. This point is emphasized, as the most constricted vessel is likely to be the most clinically important. In these experiments there was a dramatic production of cerebral vasospasm. Just what factors lead to the ion entry and the production of the pathophysiological state are presently unknown.
